Osteochondral alterations in osteoarthritis

Bone

Volumn 51, Issue 2, 2012, Pages 204-211

  Suri, Sunita ^a   Walsh, David A ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Bone; Cartilage; Osteoarthritis; Osteochondral junction; Pain; Vessels

Indexed keywords

ALENDRONIC ACID; ANGIOGENESIS INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; COLLAGENASE 3 INHIBITOR; ESTROGEN; EXTRACELLULAR SUPEROXIDE DISMUTASE; GLUCOSAMINE; GLUTATHIONE PEROXIDASE; GLUTATHIONE PEROXIDASE 9; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; NEUROTROPHIN RECEPTOR P75; PLACEBO; PPI 2458; PROTEIN TYROSINE KINASE A; RISEDRONIC ACID; SCATTER FACTOR; STRONTIUM RANELATE; TANEZUMAB; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; WNT BETEA PROTEIN; WNT INDUCED SIGNALLING PROTEIN 1; WNT PROTEIN; ZOLEDRONIC ACID;

ARTHRALGIA; ARTICLE; ARTICULAR CARTILAGE; BONE; BONE DISEASE; BONE STRUCTURE; BONE TURNOVER; BTG2 GENE; CARTILAGE CELL; CHONDROCYTE HYPERTROPHY; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; EXERCISE; GENE; GENE EXPRESSION; GPX3 GENE; HUMAN; KNEE OSTEOARTHRITIS; MAPK GENE; MOLECULAR INTERACTION; MONOTHERAPY; NONHUMAN; OSTEOARTHRITIS; OSTEOCHONDRAL JUNCTION; OSTEOCHONDRAL PLASTICITY; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; SOD2 GENE; SOD3 GENE; SUBCHONDRAL BONE; SUBCHONDRAL BONE LESION; SUBCHONDRAL BONE LOSS; SUCHONDRAL BONE LESION; SYNOVITIS; TGF ALPHA GENE; TOB1 GENE; WISP 1 GENE;

ANIMALS; BONE AND BONES; CARTILAGE, ARTICULAR; CHONDROCYTES; GENE EXPRESSION REGULATION; HUMANS; OSTEOARTHRITIS; SIGNAL TRANSDUCTION;

EID: 84861980210     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.10.010     Document Type: Article

References (80)

1. Kangarlu A., Gahunia H.K. Magnetic resonance imaging characterization of osteochondral defect repair in a goat model at 8 T. Osteoarthritis Cartilage 2006, 14:52-62.
2. Kothari A., Guermazi A., Chmiel J.S., Dunlop D., Song J., Almagor O., et al. Within-subregion relationship between bone marrow lesions and subsequent cartilage loss in knee osteoarthritis. Arthritis Care Res 2010, 62:198-203.
3. Torres L., Dunlop D.D., Peterfy C., Guermazi A., Prasad P., Hayes K.W., et al. The relationship between specific tissue lesions and pain severity in persons with knee osteoarthritis. Osteoarthritis Cartilage 2006, 14:1033-1040.
4. Felson D.T., Neogi T. Osteoarthritis: is it a disease of cartilage or of bone?. Arthritis Rheum 2004, 50:341-344.
5. Rogers J., Shepstone L., Dieppe P. Is osteoarthritis a systemic disorder of bone?. Arthritis Rheum 2004, 50:452-457.
6. Brandt K.D., Radin E.L., Dieppe P.A., van de Putte L. Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis 2006, 65:1261-1264.
7. Lories R.J., Luyten F.P. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol 2011, 7:43-49.
8. Tan A.L., Toumi H., Benjamin M., Grainger A.J., Tanner S.F., Emery P., et al. Combined high-resolution magnetic resonance imaging and histological examination to explore the role of ligaments and tendons in the phenotypic expression of early hand osteoarthritis. Ann Rheum Dis 2006, 65:1267-1272.
9. Sledge C.B., Reddi A.H., Walsh D.A., Blake D.R. Biology of the normal joint. Kelley's Textbook of Rheumatology 2001, 1-26. W.B. Saunders, Philadelphia. S. Ruddy, E.D.J. Harris, C.B. Sledge (Eds.).
10. Hunziker E.B., Quinn T.M., Hauselmann H.J. Quantitative structural organization of normal adult human articular cartilage. Osteoarthritis Cartilage 2002, 10:564-572.
11. Lyons T.J., McClure S.F., Stoddart R.W., McClure J. The normal human chondro-osseous junctional region: evidence for contact of uncalcified cartilage with subchondral bone and marrow spaces. BMC Musculoskelet Disord 2006, 7:52.
12. Hayes D.W., Brower R.L., John K.J. Articular cartilage. Anatomy, injury, and repair. Clin Podiatr Med Surg 2001, 18:35-53.
13. Walsh D.A., Bonnet C.S., Turner E.L., Wilson D., Situ M., McWilliams D.F. Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis. Osteoarthritis Cartilage 2007, 15:743-751.
14. Suri S., Gill S.E., Massena de Camin S., Wilson D., McWilliams D.F., Walsh D.A. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann Rheum Dis 2007, 66:1423-1428.
15. Hollander A.P., Dickinson S.C., Kafienah W. Stem cells and cartilage development: complexities of a simple tissue. Stem Cells 2010, 28:1992-1996.
16. Franses R.E., McWilliams D.F., Mapp P.I., Walsh D.A. Osteochondral angiogenesis and increased protease inhibitor expression in OA. Osteoarthritis Cartilage 2010, 18:563-571.
17. Clark J.M., Huber J.D. The structure of the human subchondral plate. J Bone Joint Surg Br 1990, 72:866-873.
18. Berry J.L., Thaeler-Oberdoerster D.A., Greenwald A.S. Subchondral pathways to the superior surface of the human talus. Foot Ankle 1986, 7:2-9.
19. Duncan H., Jundt J., Riddle J.M., Pitchford W., Christopherson T. The tibial subchondral plate. A scanning electron microscopic study. J Bone Joint Surg Am 1987, 69:1212-1220.
20. Walsh D.A., McWilliams D.F., Turley M.J., Dixon M.R., Franses R.E., Mapp P.I., et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 2010, 49:1852-1861.
21. Fenwick S.A., Gregg P.J., Rooney P. Osteoarthritic cartilage loses its ability to remain avascular 1999.
22. Pfander D., Cramer T., Deuerling D., Weseloh G., Swoboda B. Expression of thrombospondin-1 and its receptor CD36 in human osteoarthritic cartilage. Ann Rheum Dis 2000, 59:448-454.
23. Moses M.A., Wiederschain D., Wu I., Fernandez C.A., Ghazizadeh V., Lane W.S., et al. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci USA 1999, 96:2645-2650.
24. Fenwick S.A., Gregg P.J., Rooney P. Osteoarthritic cartilage loses its ability to remain avascular. Osteoarthritis Cartilage 1999, 7:441-452.
25. Logar D.B., Komadina R., Preželj J., Ostanek B., Trošt Z., Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab 2007, 25:219-225.
26. Gray A.W., Davies M.E., Jeffcott L.B. Localisation and activity of cathepsins K and B in equine osteoclasts. Res Vet Sci 2002, 72:95-103.
27. Bromley M., Bertfield H., Evanson J.M., Woolley D.E. Bidirectional erosion of cartilage in the rheumatoid knee joint. Ann Rheum Dis 1985, 44:676-681.
28. Strassle B.W., Mark L., Leventhal L., Piesla M.J., Jian Li X., Kennedy J.D., et al. Inhibition of osteoclasts prevents cartilage loss and pain in a rat model of degenerative joint disease. Osteoarthritis Cartilage 2010, 18:1319-1328.
29. Mapp P.I., Avery P.S., McWilliams D.F., Bowyer J., Day C., Moores S., et al. Angiogenesis in two animal models of osteoarthritis. Osteoarthritis Cartilage 2008, 16:61-69.
30. Ashraf S., Mapp P.I., Walsh D.A. Angiogenesis and the persistence of inflammation in a rat model of proliferative synovitis. Arthritis Rheum 2010, 62:1890-1898.
31. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
32. Babarina A.V., Mollers U., Bittner K., Vischer P., Bruckner P. Role of the subchondral vascular system in endochondral ossification: endothelial cell-derived proteinases derepress late cartilage differentiation in vitro. Matrix Biol 2001, 20:205-213.
33. Pufe T., Petersen W., Tillmann B., Mentlein R. The splice variants VEGF121 and VEGF189 of the angiogenic peptide vascular endothelial growth factor are expressed in osteoarthritic cartilage. Arthritis Rheum 2001, 44:1082-1088.
34. Pfander D., Kortje D., Zimmermann R., Weseloh G., Kirsch T., Gesslein M., et al. Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints. Ann Rheum Dis 2001, 60:1070-1073.
35. Bittner K., Vischer P., Bartholmes P., Bruckner P. Role of the subchondral vascular system in endochondral ossification: endothelial cells specifically derepress late differentiation in resting chondrocytesin vitro. Exp Cell Res 1998, 238:491-497.
36. Hall A.P., Westwood F.R., Wadsworth P.F. Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 2006, 34:131-147.
37. Hashimoto S., Creighton-Achermann L., Takahashi K., Amiel D., Coutts R.D., Lotz M. Development and regulation of osteophyte formation during experimental osteoarthritis. Osteoarthritis Cartilage 2002, 10:180-187.
38. Dye S.F., Vaupel G.L., Dye C.C. Conscious neurosensory mapping of the internal structures of the human knee without intraarticular anesthesia. Am J Sports Med 1998, 26:773-777.
39. Nico B., Mangieri D., Benagiano V., Crivellato E., Ribatti D. Nerve growth factor as an angiogenic factor. Microvasc Res 2008, 75:135-141.
40. Guévremont M., Martel-Pelletier J., Massicotte F., Tardif G., Pelletier J.P., Ranger P., et al. Human adult chondrocytes express hepatocyte growth factor (HGF) isoforms but not HGF: potential implication of osteoblasts on the presence of HGF in cartilage. J Bone Miner Res 2003, 18:1073-1081.
41. Pesesse L., Sanchez C., Henrotin Y. Osteochondral plate angiogenesis: a new treatment target in osteoarthritis. Joint Bone Spine 2011, 78:144-149.
42. Thambyah A., Broom N. On new bone formation in the pre-osteoarthritic joint. Osteoarthritis Cartilage 2009, 17:456-463.
43. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 86: 588-610.
44. Pfander D., Cramer T., Weseloh G., Pullig O., Schuppan D., Bauer M., et al. Hepatocyte growth factor in human osteoarthritic cartilage. Osteoarthritis Cartilage 1999, 7:548-559.
45. Sanchez C., Deberg M.A., Piccardi N., Msika P., Reginster J.Y.L., Henrotin Y.E. Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes. This effect is mimicked by interleukin-6, -1β and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis Cartilage 2005, 13:979-987.
46. Tat S.K., Pelletier J.P., Velasco C.R., Padrines M., Martel-Pelletier J. New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?. Keio J Med 2009, 58:29-40.
47. Aigner T., Fundel K., Saas J., Gebhard P.M., Haag J., Weiss T., et al. Large-scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis. Arthritis Rheum 2006, 54:3533-3544.
48. Yagi R., McBurney D., Laverty D., Weiner S., Horton W.E. Intrajoint comparisons of gene expression patterns in human osteoarthritis suggest a change in chondrocyte phenotype. J Orthop Res 2005, 23:1128-1138.
49. Brew C.J., Clegg P.D., Boot-Handford R.P., Andrew J.G., Hardingham T. Gene expression in human chondrocytes in late osteoarthritis is changed in both fibrillated and intact cartilage without evidence of generalised chondrocyte hypertrophy. Ann Rheum Dis 2010, 69:234-240.
50. Appleton C.T., Usmani S.E., Bernier S.M., Aigner T., Beier F. Transforming growth factor alpha suppression of articular chondrocyte phenotype and Sox9 expression in a rat model of osteoarthritis. Arthritis Rheum 2007, 56:3693-3705.
51. Appleton C.T., Usmani S.E., Mort J.S., Beier F. Rho/ROCK and MEK/ERK activation by transforming growth factor-alpha induces articular cartilage degradation. Lab Invest 2010, 90:20-30.
52. Blom A.B., Brockbank S.M., van Lent P.L., van Beuningen H.M., Geurts J., Takahashi N., et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthritis Rheum 2009, 60:501-512.
53. Blom AB, van Lent PL, van der Kraan PM, van den Berg WB. To seek shelter from the WNT in osteoarthritis? WNT-signaling as a target for osteoarthritis therapy. Curr Drug Targets 11: 620-629.
54. Chan B.Y., Fuller E.S., Russell A.K., Smith S.M., Smith M.M., Jackson M.T., et al. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage 2011, 19:874-885.
55. Zhang X., Zara J., Siu R.K., Ting K., Soo C. The role of NELL-1, a growth factor associated with craniosynostosis, in promoting bone regeneration. J Dent Res 2010, 89:865-878.
56. Russell R.G. Bisphosphonates: the first 40 years. Bone 2011, 49:2-19.
57. Giner M., Rios M.J., Montoya M.J., Vázquez M.A., Miranda C., Pérez-Cano R. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis. Eur J Pharmacol 2011, 650:682-687.
58. Agnello K.A., Trumble T.N., Chambers J.N., Seewald W., Budsberg S.C. Effects of zoledronate on markers of bone metabolism and subchondral bone mineral density in dogs with experimentally induced cruciate-deficient osteoarthritis. Am J Vet Res 2005, 66:1487-1495.
59. Podworny N.V., Kandel R.A., Renlund R.C., Grynpas M.D. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 1999, 26:1972-1982.
60. Carbone L.D., Nevitt M.C., Wildy K., Barrow K.D., Harris F., Felson D., et al. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum 2004, 50:3516-3525.
61. Spector T.D., Conaghan P.G., Buckland-Wright J.C., Garnero P., Cline G.A., Beary J.F., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 2005, 7:R625-R633.
62. Bingham C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507.
63. Garnero P., Aronstein W.S., Cohen S.B., Conaghan P.G., Cline G.A., Christiansen C., et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008, 16:660-666.
64. Kawasaki T., Kurosawa H., Ikeda H., Kim S.G., Osawa A., Takazawa Y., et al. Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial. J Bone Miner Metab 2008, 26:279-287.
65. Neogi T., Nevitt M.C., Ensrud K.E., Bauer D., Felson D.T. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing. Ann Rheum Dis 2008, 67:1427-1430.
66. Laslett L.L., Dore D.A., Quinn S.J., Winzenberg T., Boon P., Jones G. Zoledronic acid reduces bone marrow lesions and knee pain over one year. Ann Rheum Dis 2011, 70(Suppl 3).
67. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 2005, 9:267-285.
68. Renkiewicz R., Qiu L., Lesch C., Sun X., Devalaraja R., Cody T., et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003, 48:1742-1749.
69. Mitchell P.G., Magna H.A., Reeves L.M., Lopresti-Morrow L.L., Yocum S.A., Rosner P.J., et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996, 97:761-768.
70. Johnson A.R., Pavlovsky A.G., Ortwine D.F., Prior F., Man C.-F., Bornemeier D.A., et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007, 282:27781-27791.
71. Baragi V.M., Becher G., Bendele A.M., Biesinger R., Bluhm H., Boer J., et al. A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models. Arthritis Rheum 2009, 60:2008-2018.
72. Settle S., Vickery L., Nemirovskiy O., Vidmar T., Bendele A., Messing D., et al. Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis: confirmation by multivariate analysis that modulation of type ii collagen and aggrecan degradation peptides parallels pathologic changes. Arthritis Rheum 2010, 62:3006-3015.
73. Tat SK, Pelletier JP, Mineau F, Caron J, Martel-Pelletier J. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. Bone 49: 559-567.
74. Mapp P.I., Walsh D.A., Bowyer J., Maciewicz R.A. Effects of a metalloproteinase inhibitor on osteochondral angiogenesis, chondropathy and pain behavior in a rat model of osteoarthritis. Osteoarthritis Cartilage 2010, 18:593-600.
75. Freemont A.J., Peacock T.E., Goupille P., Hoyland J.A., O'Brien J., Jayson M.I. Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet 1997, 350:178-181.
76. Ashraf S., Mapp P.I., Walsh D.A. Contributions of angiogenesis to inflammation, joint damage and pain in a rat model of osteoarthritis. Arthritis Rheum 2011.
77. Abdiche Y.N., Malashock D.S., Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci 2008, 17:1326-1335.
78. Lane N.E., Schnitzer T.J., Birbara C.A., Mokhtarani M., Shelton D.L., Smith M.D., et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med 2010, 363:1521-1531.
79. Schnitzer T.J., Lane N.E., Birbara C., Smith M.D., Simpson S.L., Brown M.T. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011, 19:639-646.
80. Hsieh J.L., Shen P.C., Shiau A.L., Jou I.M., Lee C.H., Wang C.R., et al. Intraarticular gene transfer of thrombospondin-1 suppresses the disease progression of experimental osteoarthritis. J Orthop Res 2010, 28:1300-1306.